These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34013938)

  • 1. Nalmefene non-enantioselectively targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling: wet-lab techniques and
    Zhang X; Wang H; Wang Y; Li H; Wu S; Gao J; Zhang T; Xie J; Wang X
    Phys Chem Chem Phys; 2021 Jun; 23(21):12260-12269. PubMed ID: 34013938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists.
    Zhang X; Cui F; Chen H; Zhang T; Yang K; Wang Y; Jiang Z; Rice KC; Watkins LR; Hutchinson MR; Li Y; Peng Y; Wang X
    J Chem Inf Model; 2018 Apr; 58(4):816-825. PubMed ID: 29518316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling.
    Zhang X; Peng Y; Grace PM; Metcalf MD; Kwilasz AJ; Wang Y; Zhang T; Wu S; Selfridge BR; Portoghese PS; Rice KC; Watkins LR; Hutchinson MR; Wang X
    FASEB J; 2019 Aug; 33(8):9577-9587. PubMed ID: 31162938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Methamphetamine Nonenantioselectively Targeting Toll-like Receptor 4/Myeloid Differentiation Protein 2 by in Silico Simulations and Wet-Lab Techniques.
    Zhang X; Wang Y; Wang H; Li H; Zhang T; Peng Y; Wang X
    J Chem Inf Model; 2020 Mar; 60(3):1607-1613. PubMed ID: 31935095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.
    Montesinos J; Gil A; Guerri C
    Alcohol Clin Exp Res; 2017 Jul; 41(7):1257-1270. PubMed ID: 28493563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nalmefene hydrochloride on TLR4 signaling pathway in rats with lung ischemia-reperfusion injury.
    Zhang NL; Wang HQ; Yang J; Yang P; Kang P; Zhao T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):461-468. PubMed ID: 31957861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine Activates Toll-Like Receptor 4 to Induce Central Immune Signaling within the Ventral Tegmental Area and Contributes to Extracellular Dopamine Increase in the Nucleus Accumbens Shell.
    Wang X; Northcutt AL; Cochran TA; Zhang X; Fabisiak TJ; Haas ME; Amat J; Li H; Rice KC; Maier SF; Bachtell RK; Hutchinson MR; Watkins LR
    ACS Chem Neurosci; 2019 Aug; 10(8):3622-3634. PubMed ID: 31282647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Basis of Artemisinin Derivatives Inhibition of Myeloid Differentiation Protein 2 by Combined in Silico and Experimental Study.
    Qiao S; Zhang H; Sun F; Jiang Z
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia.
    Graham SH; Shimizu H; Newman A; Weinstein P; Faden AI
    Brain Res; 1993 Dec; 632(1-2):346-50. PubMed ID: 7908601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine Enantioselectively Targets Myeloid Differentiation Protein 2 and Inhibits the Toll-like Receptor 4 Signaling.
    Jiang P; Zhang C; Wang H; Li P; Du X; Wang Y; Lyukmanova E; Lin C; Wang X
    J Chem Inf Model; 2024 Jul; 64(13):5253-5261. PubMed ID: 38973303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.
    France CP; Gerak LR
    J Pharmacol Exp Ther; 1994 Sep; 270(3):992-9. PubMed ID: 7932212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the Role of the Hydroxyl Moiety at C14 in (+)-Opioid-Based TLR4 Antagonists via Wet-Lab Experiments and Molecular Dynamics Simulations.
    Gao J; Zhang C; Xu H; Zhang T; Wang H; Wang Y; Wang X
    J Chem Inf Model; 2024 Jul; 64(13):5273-5284. PubMed ID: 38921627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia.
    Yum SW; Faden AI
    Arch Neurol; 1990 Mar; 47(3):277-81. PubMed ID: 2178593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.
    Okamoto N; Mizote K; Honda H; Saeki A; Watanabe Y; Yamaguchi-Miyamoto T; Fukui R; Tanimura N; Motoi Y; Akashi-Takamura S; Kato T; Fujishita S; Kimura T; Ohto U; Shimizu T; Hirokawa T; Miyake K; Fukase K; Fujimoto Y; Nagai Y; Takatsu K
    J Biol Chem; 2017 Sep; 292(37):15378-15394. PubMed ID: 28754693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold.
    Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A
    Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism.
    Faden AI; Sacksen I; Noble LJ
    J Pharmacol Exp Ther; 1988 May; 245(2):742-8. PubMed ID: 3367315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine effects of naltrexone versus nalmefene in humans.
    Butelman ER; Fry RS; Kimani R; Reed B; Kreek MJ
    Hum Psychopharmacol; 2020 Mar; 35(2):e2726. PubMed ID: 32050055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C4b-binding protein negatively regulates TLR4/MD-2 response but not TLR3 response.
    Morita N; Yamazaki T; Murakami Y; Fukui R; Yamai I; Ichimonji I; Nakashima A; Nagaoka F; Takagi H; Miyake K; Akashi-Takamura S
    FEBS Lett; 2017 Jun; 591(12):1732-1741. PubMed ID: 28542817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.